Blood Sample Collection for Myasthenia Gravis

(EXPLORE-MG2 Trial)

Not currently recruiting at 10 trial locations
AH
HG
Overseen ByHelen Girma
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to gather information and samples from people with myasthenia gravis (MG), a condition that causes muscle weakness. The goal is to build a resource for researchers to better understand MG and improve future treatments. Participants will be recruited from outpatient clinics and must have been diagnosed with MG, showing specific symptoms or test results linked to the disease. This trial is ideal for those diagnosed within the last two years or those with specific antibodies or thymoma-related MG. As an unphased trial, it offers participants the opportunity to contribute to foundational research that could lead to breakthroughs in MG treatment.

Do I have to stop taking my current medications for the trial?

The trial information does not specify if you need to stop taking your current medications. It mainly focuses on collecting blood samples and data for myasthenia gravis research.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to better understand the characteristics and outcomes of Myasthenia Gravis (MG) among neurological outpatients. Unlike traditional studies that focus on specific drugs or therapies, this trial seeks to gather comprehensive data from patients directly within clinical settings. By observing real-world patient experiences and responses, the trial could lead to more personalized and effective treatment strategies for MG in the future.

Who Is on the Research Team?

RN

Richard Nowak, MD

Principal Investigator

Yale University

VJ

Vern Juel, MD

Principal Investigator

Duke University

Are You a Good Fit for This Trial?

Inclusion Criteria

You have the cognitive aptitude to comprehend and consent to a legal document.
You have been diagnosed with Myasthenia Gravis based on clinical presentation, seropositivity for MG-associated autoantibodies, and/or a decremental response to repetitive nerve stimulation, positive single fiber EMG or edrophonium test; and the signs and symptoms cannot be explained by any other disease process.
You must be amenable to finishing the study and attending subsequent appointments.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

Data and Sample Collection

Comprehensive clinical phenotyping linked to bio-specimen collection to understand disease characteristics

Ongoing

Follow-up

Participants are monitored for safety and effectiveness after data and sample collection

6 months

What Are the Treatments Tested in This Trial?

Interventions

  • Blood sample

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Neurological OutpatientsExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials
1,963
Recruited
3,046,000+

National Center for Advancing Translational Sciences (NCATS)

Collaborator

Trials
394
Recruited
404,000+

National Institute of Neurological Disorders and Stroke (NINDS)

Collaborator

Trials
1,403
Recruited
655,000+